Cargando…
Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations
[Image: see text] Starting from our previous finding of 14 known drugs as inhibitors of the main protease (M(pro)) of SARS-CoV-2, the virus responsible for COVID-19, we have redesigned the weak hit perampanel to yield multiple noncovalent, nonpeptidic inhibitors with ca. 20 nM IC(50) values in a kin...
Autores principales: | Zhang, Chun-Hui, Stone, Elizabeth A., Deshmukh, Maya, Ippolito, Joseph A., Ghahremanpour, Mohammad M., Tirado-Rives, Julian, Spasov, Krasimir A., Zhang, Shuo, Takeo, Yuka, Kudalkar, Shalley N., Liang, Zhuobin, Isaacs, Farren, Lindenbach, Brett, Miller, Scott J., Anderson, Karen S., Jorgensen, William L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931627/ https://www.ncbi.nlm.nih.gov/pubmed/33786375 http://dx.doi.org/10.1021/acscentsci.1c00039 |
Ejemplares similares
-
Optimization of Triarylpyridinone Inhibitors of the
Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency
por: Zhang, Chun-Hui, et al.
Publicado: (2021) -
Long‐acting and extended‐release implant and nanoformulations with a synergistic antiretroviral two‐drug combination controls HIV‐1 infection in a humanized mouse model
por: Beloor, Jagadish, et al.
Publicado: (2021) -
Identification of 14 Known Drugs as Inhibitors of
the Main Protease of SARS-CoV-2
por: Ghahremanpour, Mohammad M., et al.
Publicado: (2020) -
Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease
por: Deshmukh, Maya G., et al.
Publicado: (2021) -
Sculpting new structures
por: McDonald, Jocelyn A, et al.
Publicado: (2020)